3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Lung Neoplasms
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Hematologic Neoplasms
2
Solid Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma
1
Lung Diseases
1
Genomic Instability
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Neoplasms
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
ALK+ Advanced NSCLC
1
Interventions
Cyclophosphamide
61
Rituximab
50
fludarabine
34
Prednisone
33
Doxorubicin
28
Biopsy
26
Vincristine
25
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Bendamustine Hydrochloride
19
pembrolizumab
16
Lenalidomide
16
obinutuzumab
14
fludarabine phosphate
14
Etoposide
14
venetoclax
13
Tacrolimus
11
Mycophenolic Acid
10
Melphalan
10
Dexamethasone
10
zanubrutinib
9
ibrutinib
9
acalabrutinib
9
Radiotherapy
9
Gemcitabine
9
Cytarabine
9
Busulfan
9
Whole-Body Irradiation
8
Mesna
8
Filgrastim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
alectinib
×
1 year
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled